Skip to main content

Table 2 Heart Rate and Blood Pressure Response

From: Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance

Variable

Treatment

Time (min)

p-level

Pre

0

10

20

30

HR (beats/min)

PLA

58.2 ± 9.5

60.4 ± 8.1

58.6 ± 8.5

59.6 ± 8.3

60.6 ± 8.4

0.84

PWS

55.5 ± 7.3

58.2 ± 9.5

54.2 ± 7.2

56.5 ± 7.7

58.1 ± 8.1

PWS + S

56.6 ± 7.2

57.5 ± 8.8

56.5 ± 9.5

58.4 ± 9.1

60.4 ± 10.8

SBP (mmHg)

PLA

113.3 ± 7.6

114.3 ± 8.0

112.7 ± 6.8

114.3 ± 6.3

113.6 ± 6.6

0.52

PWS

111.5 ± 7.1

112.4 ± 7.3

112.9 ± 8.6

112.8 ± 7.9

112.5 ± 8.2

PWS + S

113.1 ± 7.8

112.5 ± 8.3

113.0 ± 9.6

113.9 ± 10.6

114.6 ± 10.0

DBP (mmHg)

PLA

69.6 ± 6.8

69.2 ± 6.5

68.8 ± 6.3

69.5 ± 7.4

69.1 ± 7.1

0.51

PWS

69.0 ± 6.7

70.7 ± 6.1

70.9 ± 7.1

70.6 ± 7.5

70.4 ± 7.7

PWS + S

69.6 ± 7.2

70.0 ± 6.7

71.0 ± 6.8

71.1 ± 8.1

68.4 ± 13.0

  1. Data are means ± standard deviations for Heart Rate (HR), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP). MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.28), time (p = 0.03), and treatment x time (p = 0.81). Greenhouse-Geisser univariate p-levels of interactions (treatment x time) are reported above